High incidence of discontinuations due to adverse events in patients treated with ceftaroline.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

To determine clinical outcomes in patients who received ceftaroline (Teflaro) 600 mg intravenously every 8 or 12 hours after failing or developing intolerance to first-line agents including vancomycin, daptomycin, or linezolid.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Pharmacotherapy

Title: Pharmacotherapy

ISSN (Electronic): 1875-9114

ISSN (Print): 0277-0008

Publication date (Electronic): Jul 2014

Volume: 34

Issue: 7

Affiliations

[1 ] Department of Pharmacy, University of Washington Medical Center, Seattle, Washington; School of Pharmacy, University of Washington, Seattle, Washington.

Article

DOI: 10.1002/phar.1435

PubMed ID: 24807197

SO-VID: 052897ed-d239-4e4b-b2d8-3ce0e20199a5

History

Keywords: adverse events,ceftaroline,hematologic toxicities,methicillin-resistant Staphylococcus aureus,rash

Data availability:

Keywords: adverse events, ceftaroline, hematologic toxicities, methicillin-resistant Staphylococcus aureus, rash

High incidence of discontinuations due to adverse events in patients treated with ceftaroline.

Read this article at

Abstract

Related collections

Annual Reviews Climate Change and Extreme Events

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Cited by 14